Mesenchymal Stromal Cell Therapy in Renal Recipients

Inclusion Criteria: * Subject is willing to participate in the study, must be able to give informed consent and the consent must be obtained prior to any study procedure. * Recipients of a first kidney graft from a deceased, living-unrelated or non-HLA identical living related donor \> 50 years of age. * Panel Reactive Antibodies (PRA) ≤ 10%. * Patients must be able to adhere to the study visit schedule and protocol requirements. * If female and of child-bearing age, subject must be non-pregnant, non-breastfeeding, and use adequate contraception. Exclusion Criteria: * Double organ transplant recipient. * Biopsy proven acute rejection (according to the Banff criteria) in the first 6 weeks after transplantation. * Patients with evidence of active infection or abscesses (with the exception of an uncomplicated urinary tract infection) before MSC infusion. * Patients suffering from hepatic failure. * Patients suffering from an active autoimmune disease. * Patients who have had a previous BM transplant. * A psychiatric, addictive or any disorder that compromises ability to give truly informed consent for participation in this study. * Use of any investigational drug after transplantation. * Documented HIV infection, active hepatitis B, hepatitis C or TB according to current transplantation inclusion criteria. * Subjects who currently an active opportunistic infection at the time of MSC infusion (e.g., herpes zoster \[shingles\], cytomegalovirus (CMV), Pneumocystis carinii (PCP),…